ReviewEuropean respiratory review : an official journal of the European Respiratory Society2021
Lung transplantation for interstitial lung disease.
Review in European respiratory review : an official journal of the European Respiratory Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Trial
- Effects of walking with a portable oxygen concentrator on muscle oxygenation while performing normal or pursed-lip breathing in patients with interstitial lung disease: a randomized crossover trial.Therapeutic advances in respiratory diseaseTrial
- Prognostic value of the 11-factor modified frailty index for early postoperative outcomes in elderly lung transplant recipients: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicentre retrospective analysis.Rheumatology (Oxford, England) · 2026Article
- Normalization of CEA, CA15-3, and CA27-29 Tumor Markers Following Single Lung Transplant in a Patient With a History of Early-Stage Breast Cancer and Idiopathic Pulmonary Fibrosis: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Non-pharmacological Management of Fibrosing Interstitial Lung Diseases.Tuberculosis and respiratory diseases · 2026Article
- FRED scoring system for interstitial lung disease: Predicting exacerbations requiring admissions need for long-term oxygen therapy and mortality.Lung India : official organ of Indian Chest Society · 2026Article
- The role of immune cell crosstalk and signaling pathways in the pathogenesis of pulmonary fibrosis.Molecular biology reports · 2026Review
- Assessing health-related quality of life in patients with interstitial lung diseases with and without lung transplantation using the GR-Scale.BMC pulmonary medicine · 2026Article
- Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Altered Metabolism in Idiopathic Pulmonary Fibrosis.Journal of cellular physiology · 2025Review
- Impact of reference equations on lung function and outcomes in fibrotic interstitial lung disease.ERJ open research · 2025Article
- Lung transplantation outcomes of patients with interstitial pneumonia with autoimmune features: a single-centre retrospective cohort study.Rheumatology (Oxford, England) · 2025Article
- Optimizing patient outcomes in interstitial lung disease through pre- and post-transplant management strategies.World journal of transplantation · 2025Review
- Dual Impacts of Lung Transplantation on the Recovery and Comorbidity of Interstitial Lung Diseases: A Longitudinal Assessment of the Benefits and Burden.Journal of clinical medicine · 2025Article
- Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review.Pulmonary therapy · 2025Review
- Airway complications after lung transplantation: Perioperative risk factors and clinical outcomes.JHLT open · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung transplantation (LTx) can be a life-extending treatment option for patients with advanced and/or progressive fibrotic interstitial lung disease (ILD), especially idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis, sarcoidosis and connective tissue disease-associated ILD. IPF is now the most common indication for LTx worldwide. Several unique features in patients with ILD can impact optimal timing of referral or listing for LTx, pre- or post-transplant risks, candidacy and post-transplant management. As the epidemiology of LTx and community practices have evolved, recent literature describes outcomes and approaches in higher-risk candidates. In this review, we discuss the unique and important clinical findings, course, monitoring and management of patients with IPF and other progressive fibrotic ILDs during pre-LTx evaluation and up to the day of transplantation; the need for co-management with clinical experts in ILD and LTx is emphasised. Some post-LTx complications are unique in these patient cohorts, which require prompt detection and appropriate management by experts in multiple disciplines familiar with telomere biology disorders and infectious, haematological, oncological and cardiac complications to enhance the likelihood of improved outcomes and survival of LTx recipients with IPF and other ILDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.